Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 7,
Issue 22,
November 28 2023

Featured Content

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing

This clinical guideline by Middeldorp and colleagues provides a clear, organized, and helpful update of the American Society of Hematology guidelines on venous thromboembolism management and thrombophilia testing. While randomized trials are needed, this guideline provides an overview expected to be helpful to answer most clinical questions.

Intrapatient competition of VEXAS syndrome and CML clones

Led by Djerbi et al, this is the first report of chronic myeloid leukemia (CML) and ubiquitin-like modifier-activating enzyme 1 coexistence and competition between these 2 clones in the context of CML therapy.

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

This survey by Tam et al provides important information about the unmet gaps in knowledge about patients with chronic lymphocytic leukemia (CLL), which affects their ability to participate in decision making. The results indicate that changes need to be made by physicians in the way that patients are educated and exposed to patient advisory groups and quality online material.

Natural history and variability in albuminuria in pediatric and murine sickle cell anemia

This study by Kasztan and coauthors highlights the importance of evaluating renal disease in sickle cell disease and early albuminuria screening in children. The study also demonstrates a preclinical model in transgenic sickle cell disease mice with similar findings of albuminuria. The clinical data from this study will inform clinical care practice, guideline development, and future therapeutic trials.

Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis

The findings in this article by Liang et al provide new insights into mechanisms for ineffective erythropoiesis in β-thalassemia, with particular focus on the roles of FOXO3 and CDKN1A in β-thalassemic erythropoiesis.

Vitamin C and D supplementation in acute myeloid leukemia

This retrospective analysis by Mouchel and colleagues demonstrates that vitamin C and D supplementation results in less toxicity during induction therapy in patients with acute myeloid leukemia, setting the stage for prospective studies to determine if vitamin therapy should be considered as an adjunct treatment.

Close Modal

or Create an Account

Close Modal
Close Modal